Childhood imaging radiation tied to brain tumors; tirzepatide lowers BMI in adolescents; officials confirm U.S. loss of measles elimination

A wooden stacking-ring toy with five rings narrowing toward a rounded cap on a round base.

A JAMA cohort of 3,704,860 children published Nov. 19 tied cumulative radiation from medical imaging to a dose-related rise in brain tumors, with one head CT linked to 7.9 excess tumors per 10,000 children.

Tirzepatide lowered BMI 18.5% in adolescents in a phase 3 trial, officials confirmed the U.S. loss of measles elimination status, and the Food and Drug Administration (FDA) approved adrabetadex for infantile-onset Niemann-Pick disease type C and venglustat, the first treatment for neurological symptoms of type 3 Gaucher disease.

  • Research Nov 19, 2026
    A JAMA cohort study published Nov. 19 found brain tumor risk rose with cumulative radiation dose from medical imaging in childhood and adolescence, with an excess relative risk of 1.27 per 100 mGy (95% CI 0.83 to 1.77; P < .001). By age 21, exposure comparable to one head CT was associated with 7.9 excess brain tumors per 10,000 children, according to the authors. JAMA published an accompanying commentary.
  • Research Nov 15, 2026
    In the phase 3 SURMOUNT-ADOLESCENTS trial, published in JAMA Nov. 15 and presented at ObesityWeek, 160 adolescents ages 12 to 17 with obesity were randomized to weekly tirzepatide or placebo with a lifestyle program. BMI fell 18.5% with tirzepatide and rose 0.5% with placebo at 72 weeks, an estimated treatment difference of -19.0 percentage points (95% CI -23.9 to -14.1), and 79.6% of the tirzepatide group lost at least 5% of BMI. Serious adverse events occurred in 7.4% versus 3.9%, Healio reported.
    Sources: JAMA, Healio
  • Public health Nov 17, 2026
    The U.S. has lost the measles elimination status it earned 26 years ago, officials announced Nov. 17, after the Pan American Health Organization (PAHO) found the virus had circulated uninterrupted for more than a year, Healio reported; news reports of the decision appeared Nov. 14. For the 2025-2026 school year, 92.4% of kindergarteners were fully vaccinated, according to the report. In a joint statement, Centers for Disease Control and Prevention (CDC) Director Dr. Erica Schwartz said, "The measles elimination designation is not what protects Americans. Vaccination does."
  • Public health Nov 20, 2026
    The Centers for Disease Control and Prevention (CDC) said in its Nov. 20 FluView report that seasonal flu activity continues to increase nationally. In the week ending Nov. 14, 11.8% of clinical laboratory specimens tested positive for influenza, and 352 of 365 subtyped influenza A viruses (96.4%) were A(H1N1)pdm09. Visits for influenza-like illness reached 3.8%, and seven pediatric flu deaths have been reported this season. CDC recommends annual vaccination from age 6 months and says antivirals should be started as early as possible.
    Source: CDC
  • FDA Nov 17, 2026
    The Food and Drug Administration (FDA) on Nov. 17 approved adrabetadex (Lembaz), given into the spinal canal every two weeks, to lower the risk of death in patients weighing at least 7 kg whose neurological symptoms of Niemann-Pick disease type C began before age 6. The FDA examined survival in 36 treated patients across three clinical studies and an expanded access program against a matched external control group and found a 55% reduction in the risk of death, with median survival of 8.5 years versus 4.9 years. The drug carries a boxed warning for hearing impairment, including permanent hearing loss.
    Source: FDA
  • FDA Nov 18, 2026
    The Food and Drug Administration (FDA) on Nov. 18 approved venglustat (Infilbray) tablets for neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg. A randomized, double-blind trial assigned 43 patients 12 and older previously treated with enzyme replacement therapy to the oral drug or intravenous enzyme replacement therapy; at week 52, those given the drug showed improvement on a measure combining ataxia and cognitive assessments, according to the FDA, which gave no effect sizes. Serious psychiatric risks, including suicidal ideation and behavior, have been reported. Genzyme, a Sanofi company, holds the approval.
    Source: FDA
  • Research Nov 19, 2026
    A JAMA Network Open study published Nov. 19 analyzed 26,785 children with out-of-hospital cardiac arrest in Japan's national registry. Thirty-day survival with favorable neurologic outcome was 3.6% without bystander CPR, 9.5% with compression-only CPR and 16.0% with CPR including rescue breathing, an adjusted risk ratio of 1.71 (95% CI 1.57 to 1.86). The authors said the findings support the continued importance of rescue breathing for children.

The weekly innovation roundup for pediatrics, published every Sunday for the week before; every item links to its sources. Latest pediatrics news · All specialties

Latest news

Tagged pediatrics, from the daily briefing

  1. Virginia reports a young child's measles death, its first this year, as U.S. cases pass 5,800
  2. GPT-5 missed none of the urgent primary care messages when six AI models screened patient portals in a Mass General Brigham test
  3. FDA rejects a Duchenne cell therapy, citing data integrity violations in its pivotal trial

See all the latest news